Preparation of monoclonal antibody of IV collagen and application of detection kit

By developing high specificity and high sensitivity IV collagen monoclonal antibodies and clear liposome particles, the latex-enhanced immune turbidity method is improved, solving the problem of insufficient sensitivity and specificity of existing detection methods, and achieving lower limits of detection and higher diagnostic accuracy.

CN118930649AActive Publication Date: 2024-11-12SHANGHAI REIGNCOM BIOTECHNOLOGY CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411352244.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-26
Publication Date
2024-11-12
Estimated Expiration
2044-09-26

AI Technical Summary

Technical Problem

The existing IV collagen detection methods on the market have problems of poor sensitivity, poor specificity and high false positives, especially the detection limits of latex-enhanced immune turbidity are high, which cannot meet the accurate needs of clinical diagnosis.

Method used

A high specificity and high sensitivity IV collagen monoclonal antibody was developed, combined with transparent liposome particles, which improved the latex-enhanced immune turbidity method, improved the detection signal range and sensitivity, and reduced the false positive rate. A high sensitivity and high specificity IV collagen detection kit was prepared.

Benefits of technology

The minimum detection limit is achieved to reach 3ng/ml, the clinical false positive rate is less than 5‰, and the detection range is above 600.00ng/ml, which significantly improves the accuracy of clinical diagnosis and the reliability of detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930649A_ABST
    Figure CN118930649A_ABST
Patent Text Reader

Abstract

The invention discloses preparation of a monoclonal antibody of collagen IV and application of a detection kit, and belongs to the field of immunological determination. A high-specificity conservative fragment of IV collagen protein is expressed, a polyclonal antibody is prepared for the fragment, a pair of IV monoclonal antibodies with high specificity, high affinity and high sensitivity is obtained through screening, and a double-particle-size liposome particle coating technology is matched, so that the high-specificity, high-affinity and high-sensitivity IV monoclonal antibodies are obtained. The high-sensitivity and high-specificity IV collagen detection kit and the detection method are established, the lowest detection limit is about 3ng / ml, the clinical false positive rate is lower than 0.5%, the detection range reaches 600.00 ng / ml or above, and improvement of the accuracy of clinical diagnosis is facilitated.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of immunological determination, and relates to the preparation of a monoclonal antibody for IV collagen and the application of a detection kit, and in particular to the preparation of a highly specific and highly sensitive IV collagen monoclonal antibody and the development of a latex-enhanced immunoturbidimetric kit for the quantitative detection of IV collagen. Background Art

[0002] Collagen IV (type IV collagen, IV-C) is a member of the collagen family. It belongs to non-fibrillar collagen and also has a unique heterotrimeric helical chain structure, which is composed of six types of α-peptide chains: α1, α2, α3, α4, α5, and α6. The genes COL4A1 and COL4A2 that synthesize α1 and α2 peptide chains exist in pairs on human chromosome 13. The genes COL4A3 and COL4A4 synthesize α3 and α4 peptide chains, which exist in pairs on human chromosome 2. The genes COL4A5 and COL4A6 that synthesize α5 and α6 peptide chains exist in pairs on human chromosome X. Type V collagen is the most abundant structural basement membrane component. It consists of a major triple helical structure, flanked by an N-terminal 7S domain and a C-terminal non-collagenous domain NC1. There are six different type IV collagen chains, α1-α6 (IV), which show tissue-specific distribution patterns. The three α chains fold to form a heterotrimeric molecule called the prototype. Six genetically different α chains assemble together to form only three prototypes: α1α1α2(IV), α3α4α5(IV) and α5α5α6(IV). The main form of type IV collagen, α1α1α2(IV), is present in the basement membrane of all tissues, while the other two forms are only present in some basement membranes. IV-C not only plays an important role in the formation of the BMs skeleton, but also has the function of participating in important physiological processes such as cell adhesion, migration, growth, proliferation and differentiation. For example, in gastric cancer tissue, the α5 and α6-peptide chains of BMs will be lost to varying degrees as the disease progresses. When colorectal cancer, pancreatic cancer, extrahepatic bile duct cancer and other tumors occur, the IV-C type of BMs will also change accordingly. For example, during the embryonic development of the kidneys of patients with Alport syndrome (AS), due to mutations in the gene encoding the α-peptide chain, the α3α4α5 heterotrimer cannot effectively replace the α1α1α2 heterotrimer, the glomerular filtration network is relatively weak, and is susceptible to oxidative damage and pressure damage, resulting in progressive renal failure. Therefore, the biological characteristics of IV-C are closely related to a variety of major diseases such as tumors and kidney diseases.

[0003] Type IV collagen is an indicator mainly used to observe liver cirrhosis. Its concentration is related to the degree of liver fibrosis. In liver fibrosis tissue, the expression of IV-C increases by about 14 times. The degree of liver cirrhosis can be inferred from the serum type IV collagen concentration. In acute hepatitis, although a large number of liver cells are destroyed, there is no obvious connective tissue hyperplasia, so the serum type IV collagen concentration is not significantly different from that of healthy people. In patients with chronic hepatitis, cirrhosis, and liver cancer, serum type IV collagen is significantly increased, and the degree of increase is primary liver cancer, cirrhosis, chronic active hepatitis, chronic persistent hepatitis, and acute viral hepatitis.

[0004] The commonly used methods for IV collagen detection on the market are: enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, time-resolved fluorescence immunoassay, latex-enhanced immunoturbidimetry, chemiluminescence, etc. Among them, ELISA is a manual operation, cannot be tested in batches, and the detection time is long. Radioimmunoassay technology requires the use of rare metals for labeling, and chemiluminescence requires specific equipment and is easily interfered. In the above turbidimetric method, a small amount of small antigen-antibody complex is extremely difficult to form turbidity unless it is placed for a long time; if a larger complex is formed, the amount of antigen and antibody is also large, which obviously does not meet the requirements of microquantity. Therefore, the latex-enhanced immunoturbidimetry (PETIA) that is now widely used in biochemical analyzers was developed: a modified immunoturbidimetric assay based on polyclonal antibodies, which uses genetic engineering methods to combine antibodies with latex particles. When the antigen and antibody combine, an antigen-antibody-latex particle complex is formed, which enhances the reaction absorbance. The reaction solution is turbid at a certain wavelength and compared with the standard solution treated in the same way to calculate the content of the antigen in the specimen. The whole analysis process of turbidimetric determination using a biochemical analyzer takes only a few minutes. This method is more sensitive than traditional immunoturbidimetric method.

[0005] However, the IV collagen latex-enhanced immunoturbidimetric detection kit currently on the market has the disadvantages of a minimum detection limit of 20-30 ng / ml for IV collagen and a high false positive rate due to the lack of highly specific and highly sensitive monoclonal antibodies. Summary of the invention

[0006] In view of the defects in the prior art, the purpose of the present invention is to provide a monoclonal antibody preparation and detection kit application for IV collagen. The present invention expresses a highly specific conservative fragment of IV collagen protein, prepares a polyclonal antibody against the fragment, and simultaneously screens and obtains a pair of IV monoclonal antibodies with high specificity, high affinity and high sensitivity, and establishes a high-sensitivity and high-specificity IV collagen detection kit and detection method, with a minimum detection limit of about 3ng / ml, a clinical false positive rate of less than 5‰, and a detection range of more than 600.00ng / ml, which helps to improve the accuracy of clinical diagnosis.

[0007] The objective of the present invention is achieved through the following technical solutions:

[0008] In a first aspect, the present invention provides a monoclonal antibody to collagen IV, wherein the monoclonal antibody to collagen IV comprises a monoclonal antibody as shown in any one of the following (a)-(b):

[0009] (a) Monoclonal antibody IV Col Ab1 comprises heavy chain and light chain variable regions; wherein the three complementary determining region sequences of the heavy chain variable region are:

[0010] CDR1-H1: GKIRGATEYGM (as shown in SEQ ID NO. 1),

[0011] CDR1-H2: PGLRGTTGLA (as shown in SEQ ID NO. 2),

[0012] CDR1-H3: AYRRGDPGYRFGDAY (as shown in SEQ ID NO. 3);

[0013] The three complementarity determining regions of the light chain variable region are:

[0014] CDR1-L1: SGVARTTILFP (as shown in SEQ ID NO. 4),

[0015] CDR1-L2: GMGRQTPG (as shown in SEQ ID NO. 5),

[0016] CDR1-L3: ALEAYSKPP (as shown in SEQ ID NO. 6);

[0017] (b) Monoclonal antibody IV Col Ab2 comprises heavy chain and light chain variable regions; wherein the three complementary determining region sequences of the heavy chain variable region are:

[0018] CDR2-H1: GSSIMFGGAYTTRGGYATM (as shown in SEQ ID NO. 7),

[0019] CDR2-H2: PAYTLYIPGGNVTSLS (as shown in SEQ ID NO. 8),

[0020] CDR2-H3: ASYARDTGPYGFRDPY (as shown in SEQ ID NO. 9);

[0021] The three complementarity determining regions of the light chain variable region are:

[0022] CDR2-L1: STAGGAVTDTIGNPGFRA (as shown in SEQ ID NO. 10),

[0023] CDR2-L2: GATRGRNQPYGIRN (as shown in SEQ ID NO. 11),

[0024] CDR2-L3: ADLEANPYSGWTWGV (as shown in SEQ ID NO. 12).

[0025] As an embodiment of the present invention, the variable region sequences of the heavy chain and light chain of the monoclonal antibody IV Col Ab1 are shown as SEQ ID NOs.13-14, respectively; the variable region sequences of the heavy chain and light chain of the monoclonal antibody IV Col Ab2 are shown as SEQ ID NOs.15-16, respectively.

[0026] As one embodiment of the present invention, the monoclonal antibody is selected from a Fab fragment, a Fab' fragment, a F(ab')2 fragment or a single-chain antibody.

[0027] As an embodiment of the present invention, the monoclonal antibody is prepared by hybridoma technology and obtained by screening; the antigen used in the hybridoma technology is prepared by eukaryotic expression, and the antigen sequence (i.e., the amino acid sequence expressed in eukaryotes) is as follows:

[0028] sgpygakgprgehglkgekgascygpmkpgapgikgekgepassfpvkpthtvmgprgdmgqkgepglvgrkgep gpegdtgldgqkgekglpggpgdrgrqgnfgppgstgqkgdrgepglnglpgnpgqkgepgragatgkpgllgppgppgggr gtpgppgpkgprgyvgapgpqgl (SEQ ID NO. 17).

[0029] In a second aspect, the present invention provides a nucleic acid molecule comprising a nucleic acid encoding the monoclonal antibody.

[0030] In a third aspect, the present invention provides an expression vector comprising the nucleic acid molecule.

[0031] In a fourth aspect, the present invention provides a recombinant comprising the nucleic acid molecule or the expression vector.

[0032] In a fifth aspect, the present invention provides a use of the monoclonal antibody, the nucleic acid molecule, the expression vector or the recombinant in preparing a test kit for IV collagen. The test kit of the present invention is a latex enhanced immunoturbidimetric test kit.

[0033] In a sixth aspect, the present invention provides an IV collagen detection kit, the kit comprising R1 reagent, R2 reagent, and a calibrator; wherein the R2 reagent comprises the monoclonal antibody.

[0034] As an embodiment of the present invention, the R1 reagent is a Tris buffer, which comprises: 20-50mMTris pH 7.2-7.6, NaCl 30-300mM, Tween20 0.1-2% (v / v), BSA 0.5-5% (w / v), polyethylene glycol 6000 10-500mM, blocking agent 20-25mg / L, preservative 0.5-1.5% (w / v).

[0035] Furthermore, the preservative includes sodium azide; and the blocking agent includes HBR5.

[0036] As an embodiment of the present invention, the R2 reagent is an antibody-sensitized particle suspension, which comprises: antibody-sensitized particles 0.1-0.8 g / l, 20-50 mM MOPSO pH 7.2-7.6, NaCl 30-300 mM, BSA 0.1-4.0% (w / v); the antibody-sensitized particles are liposome particles coated with monoclonal antibodies.

[0037] Furthermore, the method for preparing the antibody-sensitized particles comprises the following steps:

[0038] S1. Centrifuge the liposome particles, take the supernatant, resuspend them in glycine buffer, and disperse them by ultrasonic to obtain a resuspension;

[0039] S2, adding NHS solution to the resuspension and mixing, then adding EDC solution and mixing, stirring (at room temperature), and centrifuging;

[0040] S3, dissolving and suspending the precipitate after centrifugation in step S2 with glycine buffer, sonicating, adding monoclonal antibody, stirring (at room temperature) and centrifuging;

[0041] S4, dissolving and suspending the precipitate obtained after centrifugation in step S3 with a glycine buffer, ultrasonicating, and centrifuging to obtain the antibody-sensitized particles.

[0042] Furthermore, in step S1, the diameter of the liposome particles is 100-250 nm; wherein the diameter of the liposome particles coated with the monoclonal antibody IV Col Ab1 is 200-250 nm, and the diameter of the liposome particles coated with the monoclonal antibody IV Col Ab2 is 100-120 nm.

[0043] Furthermore, in step S3, the monoclonal antibody includes at least one of monoclonal antibodies IV Col Ab1 and IV Col Ab2; wherein the mass ratio of the added amount of the monoclonal antibody IV Col Ab1 to the liposome particles is 0.2-0.4 mg:100 mg, and the mass ratio of the added amount of the monoclonal antibody IV Col Ab2 to the liposome particles is 0.5-0.8 mg:100 mg.

[0044] As an embodiment of the present invention, the calibrator is a bovine serum matrix, including Proclin-300 Tween 200

[0045] 2-2.2% (v / v), BSA1-3% (w / v).

[0046] The above percentages of the present invention are percentages of human serum matrix volume.

[0047] Compared with the prior art, the present invention has the following beneficial effects:

[0048] 1. There are many kinds of collagen in the human body, such as I, II, III, IV, and V. The IV collagen antibodies currently on the market have poor sensitivity, poor specificity, and high false positives, and are not suitable for the development of detection kits. The present invention selects the peptide chains of natural IV collagen exposed on the surface and with strong specificity, performs prokaryotic expression, prepares monoclonal antibodies for the peptide segments, and screens a pair of monoclonal antibodies IV Col Ab1 and 2 with high specificity, high affinity, and high sensitivity, which are suitable for the detection kit.

[0049] 2. The present invention continues to develop latex enhanced immunoturbidimetry, using transparent liposome particles instead of white latex microsphere particles. Due to the light transmittance of liposome particles, the range of reagent detection signals has been greatly improved, solving the high background problem of latex enhanced immunoturbidimetry; at the same time, the double-diameter liposome particles are coated with monoclonal antibodies IV Col Ab1 and 2, thereby improving the detection sensitivity and the detection range of the reagent, so that the detection sensitivity reaches about 3ng / ml, the clinical false positive rate is less than 5‰, and the detection range reaches more than 600.00ng / ml.

[0050] 3) The IV collagen detection kit of the present invention has good repeatability, stable reagents, simple operation, high sensitivity, good specificity, rapid determination, accurate and reliable determination results, and is helpful to improve the accuracy of clinical diagnosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] Other features, objects and advantages of the present invention will become more apparent from the detailed description of non-limiting embodiments made with reference to the following drawings:

[0052] Figure 1 The linear range test results of Example 1 are shown below:

[0053] Figure 2 The linear range test results of Example 2 are shown below:

[0054] Figure 3 The linear range test results of Example 3 are shown below:

[0055] Figure 4 is the calibration curve of the type IV collagen detection kit of Example 3;

[0056] Figure 5 This is a construction map of the recombinant plasmid. DETAILED DESCRIPTION

[0057] The present invention is described in detail below in conjunction with the accompanying drawings and specific embodiments. The following examples are implemented on the premise of the technical solution of the present invention, provide detailed implementation methods and specific operation processes, and will help those skilled in the art to further understand the present invention. It should be pointed out that the protection scope of the present invention is not limited to the following embodiments, and several adjustments and improvements made under the premise of the concept of the present invention all belong to the protection scope of the present invention.

[0058] The present invention provides a method for preparing a monoclonal antibody, comprising the following steps:

[0059] First, the synthesis of recombinant antigens includes the following steps:

[0060] A. Plasmid construction: Design and synthesize recombinant plasmids, determine the designed antigen amino acid sequence (as shown in SEQ ID NO.17), insert the antigen target gene (as shown in SEQ ID NO.18) into the PET32a expression vector (purchased from EMD Biosciences (Novagen)), and introduce the plasmid. The construction map of the plasmid is shown in Figure 5 shown.

[0061] B. Antigen expression: Transform the recombinant plasmid into competent E. coli (one shot TM BL21 Star TM(DE3)), high-efficiency expression. The construction of recombinant plasmids generally selects strains with genetic stability, high transformation efficiency and high plasmid yield as recipient bacteria. The present invention selects competent Escherichia coli (one shot TM BL21 Star TM (DE3)) for expression.

[0062] C. Antigen purification: The expression product is purified by Ni affinity chromatography to obtain the target protein, i.e., the recombinant antigen. The expression vector pET32a contains a sequence encoding polyhistidine, i.e., His-Tag. Therefore, a recombinant target protein with His-Tag is obtained. His-Tag can bind to metal Ni ions, which is beneficial for the purification of the target protein. The protein with His-Tag can be purified by Ni affinity chromatography under non-denaturing conditions.

[0063] Secondly, the preparation method of IV collagen monoclonal antibody comprises the following steps:

[0064] A. Immunization of animals: Primary immunization: Select 6-8 week old female BALB / c mice, fully emulsify the antigen (60ug / mouse) with Freund's complete adjuvant, and inject it subcutaneously at multiple points, three weeks apart; Second immunization, the same dosage and route, add Freund's incomplete adjuvant, three weeks apart; Third immunization, the same dosage, no adjuvant, intraperitoneal injection. Booster immunization: 60ug, intraperitoneal injection, spleen fusion after three days.

[0065] B. Cell fusion: Take immunized BALB / c mice. Kill the mice by cervical dislocation and soak them in 75% alcohol for 5 minutes. Remove the spleen and grind it into a cell suspension. Prepare a single cell suspension with 1*10 per mouse. 8 -3*10 8 spleen cells. 8 Splenocytes and 1*10 7 After myeloma cells are fused, they are subcultured in complete culture medium.

[0066] C. Screening and cloning of hybridoma positive clones: Hybridoma cells can be screened about 2 weeks after fusion, and the Elisa method is used for primary screening. Positive clones that pass the primary screening can be cloned. After obtaining hybridomas targeting the predetermined antigen, 2-3 consecutive clonings are performed.

[0067] D.Mass preparation of monoclonal antibodies: Monoclonal antibodies are prepared in large quantities using in vitro culture method.

[0068] E. Antibody purification and identification: Monoclonal antibodies were purified using the caprylic acid-ammonium sulfate two-step precipitation method. Natural antigens were used for specific detection.

[0069] Two type IV collagen monoclonal antibodies, IV Col Ab1 and IV Col Ab2, were obtained and sequenced and immunoglobulin domain sequence analyzed. The sequences are as follows:

[0070] Among them, the three heavy chain complementary determining regions of monoclonal antibody IV Col Ab1 are:

[0071] CDR1-H1: GKIRGATEYGM (as shown in SEQ ID NO. 1),

[0072] CDR1-H2: PGLRGTTGLA (as shown in SEQ ID NO. 2),

[0073] CDR1-H3: AYRRGDPGYRFGDAY (as shown in SEQ ID NO. 3);

[0074] Three light chain complementary determining regions of monoclonal antibody IV Col Ab1:

[0075] CDR1-L1: SGVARTTILFP (as shown in SEQ ID NO. 4),

[0076] CDR1-L2: GMGRQTPG (as shown in SEQ ID NO. 5),

[0077] CDR1-L3: ALEAYSKPP (as shown in SEQ ID NO. 6);

[0078] Three heavy chain complementarity determining regions of monoclonal antibody IV Col Ab2:

[0079] CDR2-H1: GSSIMFGGAYTTRGGYATM (as shown in SEQ ID NO. 7),

[0080] CDR2-H2: PAYTLYIPGGNVTSLS (as shown in SEQ ID NO. 8),

[0081] CDR2-H3: ASYARDTGPYGFRDPY (as shown in SEQ ID NO. 9);

[0082] Three light chain complementary determining regions of monoclonal antibody IV Col Ab2:

[0083] CDR2-L1: STAGGAVTDTIGNPGFRA (as shown in SEQ ID NO. 10),

[0084] CDR2-L2: GATRGRNQPYGIRN (as shown in SEQ ID NO. 11),

[0085] CDR2-L3: ADLEANPYSGWTWGV (as shown in SEQ ID NO. 12).

[0086] The variable region sequences of the heavy chain and light chain of the monoclonal antibody IV Col Ab1 are shown in SEQ ID NOs. 13-14, respectively; the variable region sequences of the heavy chain and light chain of the monoclonal antibody IV Col Ab2 are shown in SEQ ID NOs. 15-16, respectively.

[0087] Example 1

[0088] This embodiment provides a IV collagen detection kit, and the preparation method thereof is as follows:

[0089] First, antibody-sensitized particles are prepared, including the following steps:

[0090] Take 10 ml (1000 mg) of 100 nm liposome particles and coat them with the treated IV Col Ab2 antibody according to the following steps (1)-(5):

[0091] (1) Take 10 ml of liposome particles and centrifuge at 20,000 rpm for 30 min at 4°C; remove the supernatant, resuspend in 50 mM glycine buffer at a volume 5 times that of the liposome particles, disperse by ultrasonication for 2 min, and set aside;

[0092] (2) Take 10 ml of the resuspended liposome particles, add 0.690 ml of 100 mg / ml NHS solution and mix well, then add 1.435 ml of 10 mg / ml EDC solution and mix well. Stir at room temperature for 30 min, and then centrifuge at 4°C and 20,000 rpm for 30 min.

[0093] (3) The precipitate obtained after centrifugation in step (2) was dissolved and suspended in 10 ml of 25 mM glycine buffer (purchased from Xibao Biotechnology), sonicated for 1 minute, and 6 mg of IV Col Ab1 was added. The mixture was stirred at room temperature for 90 minutes, and centrifuged at 4°C and 20,000 rpm for 15 minutes. The precipitate was dissolved and suspended in 10 ml of 25 mM glycine buffer, sonicated for 1 minute, and centrifuged at 4°C and 20,000 rpm for 20 minutes.

[0094] (4) The precipitate obtained after centrifugation in step (3) was suspended in 10 ml of 0.5% glycine buffer, sonicated for 1 minute, and then centrifuged at 4°C and 20,000 rpm for 25 minutes to obtain the antibody-sensitized particles IV Col Ab2.

[0095] Secondly, the IV collagen test kit, the components of which are as follows:

[0096] R1 reagent:

[0097] The R1 reagent is a Tris buffer, which consists of: 50 mM Tris pH 7.6, 300 mM NaCl, 1% (v / v) Tween20, 2% (w / v) BSA, 500 mM polyethylene glycol 6000, 0.9% (w / v) sodium azide, and 20 mg / L HBR5 blocker (purchased from Nanjing Jingda Biotechnology).

[0098] R2 reagent:

[0099] R2 reagent is an antibody-sensitized particle suspension, which includes: antibody-sensitized particles (IV Col Ab2-sensitized particles) 0.6 g / l, MOPSO 50 mM / L, NaCl 300 mM / L, BSA 1.0% (w / v) pH 7.4;

[0100] The calibrator was a bovine serum matrix, including: ProClin-300 Tween-20 2% (v / v), BSA 1% (w / v);

[0101] The above ingredients can be added sequentially at room temperature, or added simultaneously, or packaged separately and prepared immediately before testing.

[0102] Example 2

[0103] This embodiment provides a IV collagen detection kit, and the preparation method thereof is as follows:

[0104] First, antibody-sensitized particles are prepared, including the following steps:

[0105] Take 10 ml (1000 mg) of 220 nm liposome particles and coat them with the treated IV Col Ab1 antibody according to the following steps (1)-(5):

[0106] (1) Take 10 ml of liposome particles and centrifuge at 20,000 rpm for 30 min at 4°C; remove the supernatant, resuspend in 50 mM glycine buffer at a volume 5 times that of the liposome particles, disperse by ultrasonication for 2 min, and set aside;

[0107] (2) Take 10 ml of the resuspended liposome particles, add 0.30 ml of 100 mg / ml NHS solution and mix well, then add 1.435 ml of 10 mg / ml EDC solution and mix well, stir at room temperature for 30 min, and then centrifuge at 4°C and 20,000 rpm for 30 min.

[0108] (3) The precipitate obtained after centrifugation in step (2) was dissolved and suspended in 10 ml of 25 mM glycine buffer, sonicated for 1 minute, and 2.5 mg of IV Col Ab1 was added. The mixture was stirred at room temperature for 90 minutes, and centrifuged at 4°C and 20,000 rpm for 15 minutes. The precipitate was dissolved and suspended in 10 ml of 25 mM glycine buffer, sonicated for 1 minute, and centrifuged at 4°C and 20,000 rpm for 20 minutes.

[0109] (4) The precipitate obtained after centrifugation in step (3) was suspended in 10 ml of 0.5% glycine buffer, sonicated for 1 minute, and then centrifuged at 4°C and 20,000 rpm for 25 minutes to obtain the antibody-sensitized particles IV Col Ab1.

[0110] Secondly, the IV collagen test kit, the components of which are as follows:

[0111] R1 reagent:

[0112] The R1 reagent is a Tris buffer, which consists of: 50 mM Tris pH 7.6, 300 mM NaCl, 1% (v / v) Tween20, 2% (w / v) BSA, 500 mM polyethylene glycol 6000, 0.9% (w / v) sodium azide, and 20 mg / L HBR5 blocker (purchased from Nanjing Jingda Biotechnology).

[0113] R2 reagent:

[0114] R2 reagent is an antibody-sensitized particle suspension, which includes: antibody-sensitized particles (IV Col Ab1-sensitized particles) 0.5 g / l, MOPSO 50 mM / L, NaCl 300 mM / L, BSA 1.0% (w / v) pH 7.4;

[0115] The calibrator was a bovine serum matrix, including: ProClin 300 Tween-20 2% (v / v), BSA 1% (w / v);

[0116] The above ingredients can be added sequentially at room temperature, or added simultaneously, or packaged separately and prepared immediately before testing.

[0117] Example 3

[0118] This embodiment provides an IV collagen detection kit, and its R2 preparation method is basically the same as that of Embodiment 1 and Embodiment 2, except that: R2 reagent is a mixture of R2 reagent prepared in Embodiment 1 and R2 reagent prepared in Embodiment 2 in a ratio of 1:1 (volume ratio).

[0119] R1 reagent:

[0120] The R1 reagent is a Tris buffer, which consists of: 50 mM Tris pH 7.6, 300 mM NaCl, 1% (v / v) Tween20, 2% (w / v) BSA, 500 mM polyethylene glycol 6000, 0.9% (w / v) sodium azide, and 20 mg / L HBR5 blocker (purchased from Nanjing Jingda Biotechnology).

[0121] R2 reagent;

[0122] Antibody sensitized particles (IV Col Ab1 sensitized particles) 0.25 g / l, antibody sensitized particles (IV Col Ab2 sensitized particles) 0.3 g / l, MOPSO 50 mM / L, NaCl 300 mM / L, BSA 1.0% (w / v) pH 7.4;

[0123] The calibrator was a bovine serum matrix, including: ProClin-300 Tween-20 2% (v / v), BSA 1% (w / v);

[0124] The above ingredients can be added sequentially at room temperature, or added simultaneously, or packaged separately and prepared immediately before testing.

[0125] Example 4

[0126] This embodiment provides a IV collagen detection kit, and its R2 preparation method is basically the same as that of Example 1, except that the diameter of the liposome particles used is 150 nm, and the antibody used for coating is a sheep anti-human IV collagen polyclonal antibody purchased from Biospacific.

[0127] This embodiment also provides an IV collagen detection kit, the components of which are as follows:

[0128] R1 reagent:

[0129] The R1 reagent is a Tris buffer, which consists of: 50 mM Tris pH 7.6, 300 mM NaCl, 1% (v / v) Tween20, 2% (w / v) BSA, 500 mM polyethylene glycol 6000, 0.9% sodium azide, and 20 mg / L HBR5 blocker (purchased from Nanjing Jingda Biotechnology).

[0130] R2 reagent;

[0131] R2 reagent is an antibody sensitized particle suspension, which includes: antibody sensitized particles (sheep anti-human IV collagen polyclonal antibody sensitized particles) 0.5g / l, MOPSO 50mM / L, NaCl 300mM / L, BSA 1.0% (w / v) pH 7.4;

[0132] The calibrator was a bovine serum matrix, including: ProClin 300 Tween-20 2% (v / v), BSA 1% (w / v);

[0133] The above ingredients can be added sequentially at room temperature, or added simultaneously, or packaged separately and prepared immediately before testing.

[0134] Add them sequentially, or add them simultaneously, or package them separately and prepare them immediately before testing.

[0135] Example 5

[0136] This embodiment provides an IV collagen detection kit, and its R2 preparation method is basically the same as that of embodiment 3, except that IV Col Ab1 and IV Col Ab2 are replaced by a pair of mouse anti-human IV collagen monoclonal antibodies purchased from Biospacific.

[0137] This embodiment also provides an IV collagen detection kit, the components of which are as follows:

[0138] R1 reagent:

[0139] The R1 reagent is a Tris buffer, which is composed of: 50mM Tris pH 7.6, 300mM NaCl, 1% (v / v) Tween20, 2% (w / v) BSA, 500mM polyethylene glycol 6000, 0.9% (w / v) sodium azide, and 20mg / L HBR5 blocker (purchased from Nanjing Jingda Biotechnology).

[0140] R2 reagent;

[0141] R2 reagent is an antibody sensitized particle suspension, which includes: antibody sensitized particles (mouse anti-human IV collagen monoclonal antibody sensitized particles) 0.5g / l, MOPSO 50mM / L, NaCl 300mM / L, BSA 1.0% (w / v) pH 7.4;

[0142] The calibrator was a bovine serum matrix, including: Prolin 300 Tween-20 2% (v / v), BSA 1% (w / v);

[0143] The above ingredients can be added sequentially at room temperature, or added simultaneously, or packaged separately and prepared immediately before testing.

[0144] Add them sequentially, or add them simultaneously, or package them separately and prepare them immediately before testing.

[0145] Effect test

[0146] Hitachi 7180 fully automatic biochemical analyzer was used, and the analysis method was: two-point endpoint method, that is, the dosage of reagents R1 and R2 were 180ul and 60ul respectively, and the sample volume was 6ul; 180ul reagent R1 was added to 3ul sample and incubated at 37℃ for 5min, then 60ul R2 was added, and A1 was read after a delay of 0.5min, and then A2 was read after incubation at 37℃ for 4.5min; the main detection wavelength was 570nm. The detection conditions and determination method are shown in Table 1 below (the calibration curve of the type IV collagen detection kit of Example 3 is referenced Figure 4 ):

[0147] Table 1: Test parameters

[0148]

[0149]

[0150] Comparison and verification data

[0151] 1. Minimum detection limit comparison test results

[0152] The purpose of this experiment is to compare the minimum detection sensitivity of the reagents of Example 1, Example 2, and Example 3 in clinical samples.

[0153] The reagents of Example 1, Example 2, and Example 3, standard products, blank solutions (generally physiological saline and purified water), and normal human serum samples are used.

[0154] Machine: Hitachi 7170 automatic biochemical analyzer.

[0155] Operation steps: Use physiological saline or deionized water to dissolve the sample, then dilute it by 50% into 5 points, test each sample 5 times together with the zero point, calculate the average value, and obtain the SD value.

[0156] Result analysis: As shown in Table 2, based on the test data, calculate the SD value and CV value, calculate 1SD and 2SD respectively, and start from the smallest value. The value of the average value - 2SD above the zero point average value + 2SD is the minimum detection sensitivity of the reagent.

[0157] Table 2: Minimum detection limit comparison results

[0158]

[0159]

[0160] The experimental results show that the minimum detection limit of Example 1 of the present invention is 50ng / ml, and the minimum detection limit of Examples 2 and 3 is 3.12ng / ml. The minimum detection line of Implementation Cases 2 and 3 is better than that of Implementation Case 1. The use of large-size liposome microspheres can improve the detection sensitivity of the reagent. The detection limit of Implementation Case 5 is greater than 50ng / ml. A pair of mouse anti-human type IV collagen monoclonal antibodies was purchased. Although the double-size liposome particle coating technology was also used, the reaction sensitivity was low, which may be due to the weak antibody-antigen binding affinity.

[0161] 2. Comparison of linear range

[0162] Take a high-value sample with a concentration of about 600.00 ng / mL and use 0.9% NaCl solution as a diluent. Dilute it into 5 points at a ratio of 0.025, 0.2, 0.4, 0.6, and 0.8, add the high-value sample, and a total of 6 samples are measured 3 times according to the standard experimental operation steps, and the measurement mean is calculated respectively. The linear range curves of Examples 1-3 are shown as follows: Figure 1-3 The test results are shown in Table 3 below.

[0163] Table 3: Linearity test results

[0164]

[0165] The experimental results show that the linear high value of the reagents of Example 1 and Example 3 provided by the present invention can reach a concentration of 600 ng / mL, which is better than Example 2. The use of small-particle liposome microspheres can improve the detection linear range of the reagent. The use of liposome microspheres with mixed large and small particle sizes can not only improve the detection sensitivity but also improve the detection range of the reagent.

[0166] 3. Cross-reaction

[0167] Cross-reaction studies consider the effects of structural analogs of the analyte, nucleic acid fragments with homologous sequences, other pathogens that are likely to cause the same or similar clinical symptoms, other microorganisms that normally parasitize or are prone to complications at the sampling site, reported cross-substances, and cross-substances introduced by raw material production on the results of product testing. This experimental study analyzes the cross-interference of type I collagen, type II collagen, type III collagen, and type V collagen on reagents.

[0168] Table 4: Interference sample preparation

[0169]

[0170] Table 5: Cross-reactivity assay results

[0171]

[0172] The experimental results show that Example 4 uses a commercially available sheep anti-human type IV collagen polyclonal antibody for coating, which has different degrees of interference with homologous proteins such as type I collagen, type II collagen, type III collagen, and type V collagen. Example 5 uses a commercially available pair of mouse anti-human type IV collagen monoclonal antibodies for coating, which has no cross-reaction with type I collagen and type III collagen, and has a certain degree of cross-reaction with type II collagen and type V collagen. Example 3 is a reagent of this scheme, which has no cross-reaction with homologous proteins such as type I collagen, type II collagen, type III collagen, and type V collagen.

Claims

1. A monoclonal antibody against collagen IV, characterized in that: The IV collagen monoclonal antibody includes the monoclonal antibody shown in any one of the following (a)-(b): (a) Monoclonal antibody IV Col Ab1 comprises heavy chain and light chain variable regions; wherein the three complementary determining region sequences of the heavy chain variable region are: CDR1-H1: GKIRGATEYGM, CDR1-H2:PGLRGTTGLA, CDR1-H3:AYRRGDPGYRFGDAY; The three complementary determining region sequences of the light chain variable region are: CDR1-L1: SGVARTTILFP, CDR1-L2: GMGRQTPG, CDR1-L3:ALEAYSKPP; (b) Monoclonal antibody IV Col Ab2 comprises heavy chain and light chain variable regions; wherein the three complementary determining region sequences of the heavy chain variable region are: CDR2-H1:GSSIMFGGAYTTRGGYATM, CDR2-H2:PAYTLYIPGGNVTSLS, CDR2-H3:ASYARDTGPYGFRDPY; The three complementary determining region sequences of the light chain variable region are: CDR2-L1: STAGGAVDTIGNPGFRA, CDR2-L2:GATRGRNQPYGIRN, CDR2-L3:ADLEANPYSGWTWGV.

2. The IV collagen monoclonal antibody according to claim 1, characterized in that The variable region sequences of the heavy chain and light chain of the monoclonal antibody IV ColAb1 are shown in SEQ ID NOs. 13-14, respectively; the variable region sequences of the heavy chain and light chain of the monoclonal antibody IV Col Ab2 are shown in SEQ ID NOs. 15-16, respectively.

3. The IV collagen monoclonal antibody according to claim 1, characterized in that: The monoclonal antibody is prepared by hybridoma technology and obtained by screening; the antigen used in the hybridoma technology is prepared by eukaryotic expression; the antigen sequence is shown in SEQ ID NO.

17.

4. A nucleic acid molecule, characterized in that The nucleic acid molecule comprises a nucleic acid encoding the monoclonal antibody according to any one of claims 1 to 3.

5. An expression vector, characterized in that: The expression vector comprises the nucleic acid molecule of claim 4.

6. A recombinant, characterized in that The recombinant comprises the nucleic acid molecule according to claim 4 or the expression vector according to claim 5.

7. Use of the monoclonal antibody according to any one of claims 1 to 3, the nucleic acid molecule according to claim 4, the expression vector according to claim 5 or the recombinant according to claim 6 in the preparation of a IV collagen detection kit.

8. A IV collagen detection kit, characterized in that: The kit comprises R1 reagent, R2 reagent, and a calibrator; wherein the R2 reagent comprises the monoclonal antibody according to any one of claims 1 to 4.

9. The IV collagen detection kit according to claim 8, characterized in that: The R1 reagent is a Tris buffer, which comprises: 20-50 mM Tris pH 7.2-7.6, NaCl 30-300 mM, Tween20 0.1-2% v / v, BSA 0.5-5% w / v, polyethylene glycol 6000 10-500 mM, blocking agent 20-25 mg / L, preservative 0.5-1.5% w / v; the preservative comprises sodium azide; the blocking agent comprises HBR5; The R2 reagent is an antibody sensitized particle suspension, which comprises: antibody sensitized particles 0.1-0.8 g / l, 20-50 mM MOPSO pH 7.2-7.6, NaCl 30-300 mM, BSA 0.1-4.0% w / v; the antibody sensitized particles are liposome particles coated with monoclonal antibodies; The calibrator is a bovine serum matrix, including Proclin-300 Tween 200 2-2.2% v / v, BSA 1-3% w / v.

10. The IV collagen detection kit according to claim 9, characterized in that: The method for preparing the antibody-sensitized particles comprises the following steps: S1. Centrifuge the liposome particles, take the supernatant, resuspend them in glycine buffer, and disperse them by ultrasonic to obtain a resuspension; The diameter of the liposome particles is 100-250 nm; wherein the diameter of the liposome particles coated with the monoclonal antibody IV Col Ab1 is 200-250 nm, and the diameter of the liposome particles coated with the monoclonal antibody IV Col Ab2 is 100-120 nm; S2, adding NHS solution to the resuspension and mixing, then adding EDC solution and mixing, stirring, and centrifuging; S3, dissolving and suspending the precipitate after centrifugation in step S2 with a glycine buffer, sonicating, adding a monoclonal antibody, stirring, and centrifuging; The monoclonal antibody comprises at least one of monoclonal antibodies IV Col Ab1 and IV Col Ab2; wherein the mass ratio of the monoclonal antibody IV Col Ab1 added to the liposome particles is 0.2-0.4 mg:100 mg, and the mass ratio of the monoclonal antibody IV Col Ab2 added to the liposome particles is 0.5-0.8 mg:100 mg; S4, dissolving and suspending the precipitate obtained after centrifugation in step S3 with a glycine buffer, ultrasonicating, and centrifuging to obtain the antibody-sensitized particles.

Citation Information

Patent Citations

  • Double-liposome nanoparticle coated serum amyloid protein A detection kit

    CN112014574A

  • Collagen-localized immunomodulatory molecules and methods thereof

    CN112771071A

  • Kit and detection method for determining type IV collagen in human blood

    CN112782409A

  • Antibody of type 4 collagen alpha 5, detection kit and application thereof

    CN116162159A